Therefore, GLP-1 has demonstrated a role in renal protection trough modulation of lipid and energy metabolism, and it is supposed that GLP-1R agonists may be a promising therapy in obesity-associated CKD. This evidence concerns the gene GLP1R and obesity disorder.